Next Article in Journal
COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations
Next Article in Special Issue
“First Do No Harm”. No-Fault Compensation Program for COVID-19 Vaccines as Feasibility and Wisdom of a Policy Instrument to Mitigate Vaccine Hesitancy
Previous Article in Journal
The Epidemiological and Economic Impact of a Cell-Based Quadrivalent Influenza Vaccine in Adults in the US: A Dynamic Modeling Approach
Previous Article in Special Issue
Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
 
 
Article

Article Versions Notes

Vaccines 2021, 9(10), 1096; https://doi.org/10.3390/vaccines9101096
Action Date Notes Link
article pdf uploaded. 28 September 2021 11:24 CEST Version of Record https://www.mdpi.com/2076-393X/9/10/1096/pdf-vor
article supplementary file uploaded. 28 September 2021 11:24 CEST - https://www.mdpi.com/2076-393X/9/10/1096#supplementary
article xml file uploaded 29 September 2021 05:21 CEST Original file -
article xml uploaded. 29 September 2021 05:21 CEST Update https://www.mdpi.com/2076-393X/9/10/1096/xml
article pdf uploaded. 29 September 2021 05:21 CEST Updated version of record https://www.mdpi.com/2076-393X/9/10/1096/pdf
article html file updated 29 September 2021 05:22 CEST Original file -
article html file updated 29 September 2021 10:07 CEST Update https://www.mdpi.com/2076-393X/9/10/1096/html
Back to TopTop